spacer
home > pmps > winter 2018 > every drop counts
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Every Drop Counts

Drugs based on blood plasma or other biological microorganisms are – in comparison to chemical-based materials – expensive in their extraction. It is equally costly and complex to process these products to obtain a safe API. Even the smallest quantities represent high financial value. All processes, in particular filling and closing, and the upstream and downstream functions must be designed to generate the maximum output of pharmaceuticals from an existing product quantity.

The biopharmaceutical market is continually growing. These drugs might have the greatest potential to solve the medical challenges of the near future, such as multi-resistant germs and rare diseases.

To meet the special requirements of these expensive pharmaceuticals, the entire filling and packaging process has been analysed and revised. During this, waste caused by underfilling should be avoided, as should overfilling. If the overfill fluctuates within a defined tolerance, expensive product is involuntarily ‘given away’. On the other hand, if the fill volume is outside the tolerance, the container must be rejected. Many other factors in the manufacturing process have a significant impact on the maximised product yield, according to the experts at the Schwäbisch Hall company. These factors are explained in more detail later.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Matthias Poslovski, a graduate mechanical engineer, has been with the Optima Group since 1998. He began his career with the company as Sales Manager of the former division Inova pharma systems. From 2000 to 2002, Matthias managed the Optima division of Kugler; its expertise was in non-sterile filling and packaging technology. Today, he holds the title of Director Technical Sales at Optima Pharma. His responsibilities encompass the overall support of sales worldwide. 
spacer
Matthias Poslovski
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Mologic Signs Agreements with Medisur and Peripal to Distribute PERiPLEX POC Diagnostic in Europe

Mologic Ltd, a developer of powerful, personalised diagnostics to improve the lives of patients, today announced that it has signed agreements with medical technology companies, Medisur and Peripal AG to distribute PERiPLEX®, a rapid point-of-care (POC) test for the detection of infection in patients on peritoneal dialysis (PD). Both companies are specialists in the development and distribution of products which enable patient self-management and will supply PERiPLEX as part of a highly complementary product portfolio in key European markets including France, Germany, Italy, The Netherlands, Austria and Switzerland.
More info >>

White Papers

pAVEway™ expression system for the efficient expression of therapeutic proteins

Fujifilm Diosynth Biotechnologies

One of the major bottlenecks in the production of biopharmaceuticals is the efficient expression of therapeutic proteins in microbial or mammalian cells. The Escherichia coli pAVEway™ expression system described here has been developed to ensure high product titres and efficient scale up to GMP manufacture, whilst minimising many common issues seen in other expression systems, such as ‘leaky’ expression (expression of recombinant protein in the absence of inducer).
More info >>

 
Industry Events

SMi presents the 13th Conference on ADMET

9-10 July 2018, Holiday Inn Kensington Forum, London, UK

SMi is delighted to announce the 13th annual ADMET conference returning to London to explore the optimisation of ADMET modelling techniques, preclinical DMPK applications and development of biopharmaceuticals.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement